G

Glenmark Pharmaceuticals Ltd
NSE:GLENMARK

Watchlist Manager
Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
Watchlist
Price: 1 515.45 INR 0.69% Market Closed
Market Cap: 427.6B INR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one GLENMARK stock under the Base Case scenario is 1 115.69 INR. Compared to the current market price of 1 515.45 INR, Glenmark Pharmaceuticals Ltd is Overvalued by 26%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GLENMARK Relative Value
Base Case
1 115.69 INR
Overvaluation 26%
Relative Value
Price
G
Worst Case
Base Case
Best Case

Valuation Multiples

3.5
P/S
P/S
Price to Sales
3.5
vs History
7
vs Industry
34
Median 3Y
1.1
Median 5Y
1.2
Industry
2.4
Forward
3.1
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
0
Median 3Y
13.2
Median 5Y
13.6
Industry
20.8
Forward
29.3
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
7
Median 3Y
11.1
Median 5Y
11.1
Industry
15.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
35
Median 3Y
-7.9
Median 5Y
-7.9
Industry
22.8
More Details
5.1
P/B
P/B
Price to Book Value
5.1
vs History
9
vs Industry
15
Median 3Y
2.3
Median 5Y
2.1
Industry
2
More Details
3.3
EV/S
EV/S
Enterprise Value to Sales
3.3
vs History
7
vs Industry
35
Median 3Y
1.3
Median 5Y
1.4
Industry
2.5
Forward
2.9
More Details
5.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.1
vs History
9
vs Industry
40
Median 3Y
2
Median 5Y
2.2
Industry
4.9
More Details
27.1
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
27.1
vs History
9
vs Industry
14
Median 3Y
9.5
Median 5Y
8.3
Industry
12.7
Forward
16.2
More Details
43
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
43
vs History
14
vs Industry
10
Median 3Y
12.5
Median 5Y
10.5
Industry
15.8
Forward
20.1
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
7
Median 3Y
12.2
Median 5Y
12.4
Industry
14
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
0
Median 3Y
25.2
Median 5Y
34.2
Industry
18.3
More Details
3.8
EV/IC
EV/IC
Enterprise Value to IC
3.8
vs History
9
vs Industry
21
Median 3Y
1.5
Median 5Y
1.3
Industry
1.7
More Details

Multiples Across Competitors

GLENMARK Competitors Multiples
Glenmark Pharmaceuticals Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
427.6B INR 3.5 -48.9 27.1 43
US
Eli Lilly and Co
NYSE:LLY
775.3B USD 17.2 73.2 42.6 47
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
373.9B USD 4.2 26.6 12.5 16.4
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK 7.1 20.5 13.5 15.4
CH
Roche Holding AG
SIX:ROG
228.6B CHF 3.9 19.9 11.1 13.2
UK
AstraZeneca PLC
LSE:AZN
174.1B GBP 4.2 32.3 126.8 195.3
CH
Novartis AG
SIX:NOVN
196B CHF 4.3 18.7 11.3 14.5
US
Merck & Co Inc
NYSE:MRK
219.3B USD 3.4 12.8 8.7 10.2
IE
Endo International PLC
LSE:0Y5F
167.6B USD 72.3 -57.3 267.5 670.8
US
Pfizer Inc
NYSE:PFE
140B USD 2.2 17.4 8.4 12
P/E Multiple
Earnings Growth PEG
IN
G
Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
Average P/E: 27.7
Negative Multiple: -48.9 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
73.2
49%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
26.6
26%
1
DK
Novo Nordisk A/S
CSE:NOVO B
20.5
19%
1.1
CH
Roche Holding AG
SIX:ROG
19.9
16%
1.2
UK
AstraZeneca PLC
LSE:AZN
32.3
36%
0.9
CH
Novartis AG
SIX:NOVN
18.7
16%
1.2
US
Merck & Co Inc
NYSE:MRK
12.8
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -57.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.4
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
G
Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
Average EV/EBITDA: 397.8
27.1
41%
0.7
US
Eli Lilly and Co
NYSE:LLY
42.6
30%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.5
15%
0.9
CH
Roche Holding AG
SIX:ROG
11.1
8%
1.4
UK
AstraZeneca PLC
LSE:AZN
126.8
9%
14.1
CH
Novartis AG
SIX:NOVN
11.3
5%
2.3
US
Merck & Co Inc
NYSE:MRK
8.7
9%
1
IE
E
Endo International PLC
LSE:0Y5F
267.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
8.4
3%
2.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
G
Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
Average EV/EBIT: 1 703.6
43
68%
0.6
US
Eli Lilly and Co
NYSE:LLY
47
33%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.4
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
15.4
16%
1
CH
Roche Holding AG
SIX:ROG
13.2
9%
1.5
UK
AstraZeneca PLC
LSE:AZN
195.3
21%
9.3
CH
Novartis AG
SIX:NOVN
14.5
8%
1.8
US
Merck & Co Inc
NYSE:MRK
10.2
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
670.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
12
10%
1.2

See Also

Summary
GLENMARK intrinsic value, competitors valuation, and company profile.
DCF Valuation
GLENMARK stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GLENMARK stock valuation using valuation multiples.
Wall Street Estimates
GLENMARK price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GLENMARK stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 243,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.